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Background and Objectives: Gastroesophageal reflux
disease (GERD) is commonly associated with morbid
obesity (MO). Antireflux surgery has a higher failure rate
in MO and addresses only one of the comorbidities pres-
ent. This paper reviews the results of laparoscopic Roux-
en-Y gastric bypass (LRYGBP) performed for recalcitrant
GERD in MO.
Methods: Patients with recalcitrant GERD and a body
mass index (BMI)>35 undergoing LRYGBP were includ-
ed. LRYGB included crural repair, creation of a small gas-
tric pouch (30 mL), and intestinal bypass (150 to 180 cm).
All patients were followed in clinic and by telephone.
Results: From February 1999 to April 2001, 57 patients (51
F, 6 M) with a mean age of 43 (range, 22 to 67) and a medi-
an BMI of 43 underwent LRYGBP. Hiatal hernia or
esophagitis, or both, were present in 48, Barrett’s in 2.
LRYGBP was possible in 52 patients; 5 required open con-
version. The median hospital stay was 3 days.
Complications included 1 leak, 1 pulmonary emboli, 2
reoperations for internal roux limb hernia, and 7 gastroje-
junal strictures. At a mean follow-up of 18 months (range,
3 to 30), all patients report improvement or no symptoms
of GERD and a mean weight loss of 40 kg (range, 16 to
70). Quality of life scores (SF-36) were above national
norms for physical and mental components (median 55,
norms=50). GERD-health related quality of life median
score was <1 (scale, 0 to 45, 0=asymptomatic, 45=worse).
Conclusion: LRYGBP was effective for recalcitrant
GERD in MO. LRYGBP also led to weight loss and
improvement in other comorbidites. Surgeons with min-
imally invasive expertise should consider LRYGBP for
treatment of GERD in the morbidly obese.
INTRODUCTION
Gastroesophageal reflux disease (GERD) is one of the
most frequently occurring benign functional disorders in
Western industrial countries.1 The effectiveness of
laparoscopic antireflux surgery for recalcitrant GERD has
been clearly demonstrated in several series. Good to
excellent patient satisfaction scores have been reported
in approximately 90% of patients.2,3 These laparoscopic
results, in combination with a shorter hospital stay and a
more rapid return to normal activities, have promoted
the emergence of minimally invasive antireflux surgery
as the method of choice for the operative management
of GERD.4
Antireflux surgery has a higher failure rate in MO, which
is in direct relation to high body mass index.5 The
increased intraabdominal pressure and the morbid obe-
sity-related comorbidities lead to a higher failure rate of
the standard antireflux procedures in this group of
patients. Over the past 40 years, surgery has become the
most effective long-term treatment for morbid obesity.6
The National Institutes of Health during their Consensus
Development Conference on Gastrointestinal Surgery for
Morbid Obesity in 1991 recognized the role of bariatric
surgery in the treatment of highly selected, well-
informed, motivated patients who are acceptable opera-
tive risks and fail or are likely to fail a medical weight
loss program.7,8 Bariatric operations allow for substantial
weight loss, extended weight maintenance, and control
or reversal of obesity-related health problems.9,10 Several
series have now reported that LRYGBP improves GERD
symptoms, but few have included standardized quality of
life tools.11,12,13,14,15
The objective of this study was to evaluate the efficacy
of LRYGBP as an antireflux procedure on GERD-related
symptoms in morbidly obese patients by using a heart-
burn-related quality of life score and other standardized
outcomes tools.
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METHODS
Patients with recalcitrant GERD and a BMI greater than 35
were offered LRYGBP or Nissen fundoplication. Patients
who chose LRYGBP were included in this study. An
extensive preoperative evaluation, including history and
physical examination, the usage of antacid medication
and its efficacy, nutritional and psychiatric evaluation,
and indicated specialty consultations, was performed
before surgery. All the patients had an upper endoscopy
or upper gastrointestinal imaging to document and eval-
uate their GERD severity and upper GI anatomy.
Laboratory evaluation included complete blood count,
serum chemistries, and thyroid function testing; 24-hour
pH monitoring was done in select patients. All patients
received preoperative abdominal sonography. If gall-
stones were detected, laparoscopic cholecystectomy was
performed concomitantly.
Patient preparation for surgery consisted of a detailed
explanation in written and oral form of the developmen-
tal aspect of LRYGBP and its benefits and risks, including
short- and long-term complications, side effects, nutri-
tional sequelae, and the possibility of conversion to the
open procedure. Informed consent was obtained.
Preoperative bowel cleansing and perioperative antibi-
otics were administered. Prophylaxis against venous
thrombosis and pulmonary embolus consisted of periop-
erative pneumatic compression devices and low-dose
subcutaneous heparin.
Data were collected prospectively and verified retrospec-
tively, then entered into a customized computer database.
Data sources included office charts, follow-up notes, hos-
pital charts, and patient interview in the outpatient clinic
and phone interviews. Parameters included patient
demographics, comorbidity, hospital stay, recovery, com-
plications, weight loss, GERD symptoms, and the need
for antacids.
Quality of life changes and patient satisfaction were eval-
uated using the Heart Burn Related Quality of Life
(HRQOL) and SF-36 Quality of Life questionnaires.
Recovery was defined as the number of days after surgery
when patients resumed common activities of daily living,
such as driving, shopping, household activities, and
employment.
Follow-up weights were obtained from the University of
Pittsburgh Surgical Weight Loss Clinic scale with a capac-
ity of 400 kg. On occasion, official weights were obtained
from physician office scales or telephone interviews.
Surgical Technique
The surgical technique was a modification of the tech-
nique described by Wittgrove et al.16 The patient was
placed in a supine position with the surgeon on the right
and the assistant on the left, and 2 monitors were above
the patient’s shoulders. After creation of carbon dioxide
pneumoperitoneum (15 mm Hg) using the open Hasson
technique, cannulas (U.S. Surgical, Norwalk, CT) were
placed as shown in Figure 1. The operating table was
placed in a steep reverse Trendelenburg position. To
expose the esophagus and stomach, a 5-mm liver retrac-
tor (Genzyme, Tucker, GA) was placed through the infe-
rior right subcostal port, and the left lateral segment of
the liver was elevated. Gastric pouch creation was per-
formed. To localize the esophagogastric junction and size
the pouch, a caudate lobe of the liver is a marker for the
pouch margins. Then, a window was created in the less-
er omentum near the gastric wall at the lesser curvature.
The Endo GIA stapler (U.S. Surgical), 60-mm length and
4.8-mm staples, was inserted and applied 3 or 4 times to
staple and cut the gastric pouch with 3 rows of staples
on each side. A smaller staple size (3.5 mm) was later
substituted to reduce staple line bleeds at the transected
stomach. The patient was returned to the supine posi-
tion. The greater omentum and transverse colon were
Figure 1. The laparoscopic port placements and their use dur-
ing the procedure.passed to the upper abdomen to expose the ligament of
Treitz. To create the Roux limb, the jejunum was tran-
sected with an Endo GIA II stapler (U.S. Surgical), 45-mm
length and 3.5-mm staples, at approximately 50 cm from
the ligament of Treitz, where a comfortable length of
mesentery exists. A smaller staple size (2.5 mm) was later
substituted to reduce staple line bleeds at the transected
bowel. The jejunal mesentery was then divided with 2
applications of the Endo GIA II stapler, using the vascu-
lar load (45-mm length, 2.0-mm staples). A 6-cm length
of Penrose drain was sewn to the end of the Roux limb
using the Endostitch (U.S. Surgical). A retrogastric-retro-
colic tunnel for the Roux limb was then created. Using
ultrasonic dissection, a window was created in the meso-
colon immediately anterior and lateral to the ligament of
Treitz to gain access to the lesser peritoneal sac. The
Roux limb was then passed in a retrocolic retrogastric
fashion to lie next to the gastric pouch (Figure 2). The
gastrojejunostomy was then created using the Endo GIA
II stapler, and the gastrojejunostomy anastomosis was
closed with interrupted 2–0 Surgideck suture material
(U.S. Surgical) using the Endostitch. The gastrojejunosto-
my and enterotomy site were endoscopically inspected
and tested for leakage after insufflation and submerging
them in irrigation fluid. The patient was returned to the
supine position to create the jejunojejunostomy. The
Roux limb was then measured 150 to 180 cm distally, and
a stapled side-to-side anastomosis was created with the
proximal jejunal limb using 1 application of the Endo
GIA stapler II (60-mm length, 3.5-mm staples). Later, a
2.5-mm staple cartridge was used. The enterotomy sites
were stapled closed, and the mesentery of the jejunoje-
junostomy was sutured closed (Figure 2).
Patients began ambulating on the evening of surgery.
Pain management consisted of morphine patient-con-
trolled analgesia (PCA) intravenously as needed. An
upper gastrointestinal series was performed on the morn-
ing of the first postoperative day using Gastrografin fol-
lowed by barium. A clear liquid diet was begun that day,
and the patient was discharged from the hospital after
demonstrating tolerance for the diet and return of bowel
function, usually on the second postoperative day.
Patient follow-up was scheduled for every 2 months,
with laboratory evaluation every 6 months, until weight
loss stabilized (usually 1 to 1.5 years after surgery), then
twice per year. All the patients are routinely treated with




From February 1999 to April 2001, 57 patients with a
median BMI of 43 underwent attempted LRYGBP at the
thoracic division of the University of Pittsburgh Medical
Center. Demographics are listed in Table 1.
Hiatal hernia or esophagitis, or both, were present in 48
patients; Barrett’s esophagus was documented in 2.
LRYGB was possible in 52 patients; 5 required open con-
version, 3 due to multiple adhesions and 2 for poor
Table 1.










Figure 2. The completed gastric bypass: gastric pouch-jejunal
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exposure. The median hospital stay was 3 days (range, 3
to 9). Complications included 1 leak, 1 pulmonary
emboli, 2 reoperations for internal roux intestinal limb
hernia, and 7 gastrojejunal strictures, which were treated
with endoscopic dilatations, average of 1 postoperative
dilatation (range, 1 to 3). No deaths occurred. At a mean
follow-up of 18 months (range, 3 to 30), all patients report
improvement or no symptoms of GERD and a mean
weight loss of 40 kg (range, 16 to 70). Previous and cur-
rent antacid medication usage is summarized in Table 2.
Quality of life scores (SF-36) were above national norms
for physical and mental components (median=55,
mode=50). The GERD-health related quality of life medi-
an score was <1 (scale, 0 to 45, 0=asymptomatic,
45=worse) (Table 3).
DISCUSSION
Excessive body weight is a significant independent risk
factor for a hiatal hernia and is significantly associated
with esophagitis.17 Fisher et al18 demonstrated a correla-
tion between both weight and body mass index with gas-
troesophageal reflux. Since the early 1990s, the status of
laparoscopic antireflux surgery has moved from experi-
mental to routine, with large experiences now reported
by many centers.17 Furthermore, the outcome in the
majority of patients undergoing surgery is good, with
relief of reflux symptoms in about 90% of the patients.20
Laparoscopic surgery for the correction of gastroe-
sophageal reflux has become common throughout the
western world,21 partly because of better patient accept-
ance due to a perception that surgical procedures are
now less invasive and also because of an apparently
increasing incidence of reflux presenting as a clinical
problem.
Our series of patients is the first description and evalua-
tion of the LRYGBP as an antireflux procedure.
Previously, it was reported that one of the major mor-
bidities after ring vertical gastroplasty is severe acid
reflux22,23; the Roux-en-Y gastric bypass suggests a solu-
tion to this complication although it has never been stud-
ied from the perspective of treating gastroesophageal
reflux disease. All the patients in this study had sympto-
matic GERD, and they opted to be treated with LRYGBP
to address the initial GERD problem and the other
comorbidities associated with their morbid obesity. They
were all treated with low-dose Ranitidine hydrochloride
postoperatively to prevent anastomotic ulcers; however,
the dosage used is nontherapeutic for GERD symptoms.
The use of antacid medications after the surgery was in
less than 10% of the patients, and all of these were on a
lower dosage than that prior to the surgery. All our
patients were refractory to medical treatment before sur-
gery, and 53% were on a high dosage and a convention-
al dosage of proton pump inhibitors. All the patients
were interviewed, and the heartburn-related symptoms
were recorded. According to our results, all were free of
GERD symptoms after the operation, and it was not
always correlated to their excess body weight lost. Our
result may suggest that the antireflux mechanism of this
surgery is a combination of acid reflux reduction due to
gastric stapling or gastroplasty and the reduction of
increased intraabdominal pressure by reduction of
Table 3.
GERD-Health Related Quality of Life Scores (N=40)
HRQL: Mean, 1.945; Median, 0
HRQL Satisfaction Score: Mean, 1.108; Median, 1.0
SF-36 PCS: Mean, 57.16; Median, 55
SF-36 MCS: Mean, 52.4; Median, 55 
Table 2.
Before and After Surgery Antacid Medication Usage
Medication No.of Patients Before Surgery No.of Patients After Surgery
High dose proton pump inhibitors 17 0
Proton pump inhibitors 20 mg twice per day 14 3
High dose H2 blockers 17 All patients were treated with
low dose Ranitidine 150 mg/day
Antacids 9 2excess body weight resulting in lower intraabdominal
pressure.
CONCLUSION
LRYGBP was effective for recalcitrant GERD in this
patient population. LRYGBP also led to weight loss and
improvement in other comorbidities. Thoracic surgeons
with laparoscopic expertise should consider LRYGBP for
treatment of GERD in the MO.
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